期刊
CARDIOVASCULAR DIABETOLOGY
卷 20, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12933-021-01234-5
关键词
Surrogate marker; Vascular function; Vascular failure; Dipeptidyl peptidase-4 inhibitor
资金
- Uehara Memorial Foundation
Clinical trials investigating cardiometabolic therapies on cardiovascular surrogate markers can generate inconsistent and conflicting results, requiring careful investigation to understand potential cardiovascular effects. Assessing impact on surrogate markers from various perspectives and interpreting results based on clinical trial findings can aid in selecting appropriate medication tailored to individual patients.
Clinical trials are often performed to investigate the effects of various types of cardiometabolic therapies on cardiovascular surrogate markers, including vascular function and biomarkers. This study platform has the potential to provide information on the suspected actions of drugs and mechanistic insights into their prognostic impact. However, despite using the same class of drugs and similar study designs we are often faced with inconsistent and even conflicting results, possibly leading to some confusion in the clinical setting. When interpreting these results, it is important to investigate what caused the differences and carefully assess the information, taking into account the research situation and the patient population investigated. Using this approach, assessment of the impact on cardiovascular surrogate markers observed in clinical studies from multiple perspectives should help to better understand the potential cardiovascular effects. In this commentary we discuss how we should interpret the effects of cardiometabolic therapeutics on vascular surrogate markers, based on viewpoints learned from the results of clinical trials on dipeptidyl peptidase-4 inhibitors. This learning strategy could also be helpful for appropriate selection of drugs for evidence-based, patient-centric, tailored medication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据